These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

541 related items for PubMed ID: 7522962

  • 21. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
    Shin SJ, Hyjek E, Early E, Knowles DM.
    Int J Surg Pathol; 2006 Oct; 14(4):279-84. PubMed ID: 17041191
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays.
    Mayr D, Kanitz V, Amann G, Engel J, Burges A, Löhrs U, Diebold J.
    Histopathology; 2006 Jan; 48(2):149-56. PubMed ID: 16405663
    [Abstract] [Full Text] [Related]

  • 31. Mucoepidermoid carcinoma of the breast shares cytogenetic abnormality with mucoepidermoid carcinoma of the salivary gland: a case report with molecular analysis and review of the literature.
    Camelo-Piragua SI, Habib C, Kanumuri P, Lago CE, Mason HS, Otis CN.
    Hum Pathol; 2009 Jun; 40(6):887-92. PubMed ID: 19200580
    [Abstract] [Full Text] [Related]

  • 32. [About the prognostic value of Her-2 gene-amplification and cell-proliferation in salivary duct carcinoma of the major salivary glands - a pilot-study].
    Jaehne M, Jäkel KT, Röser K, Ussmüller J, Löning T.
    Laryngorhinootologie; 2001 Sep; 80(9):525-9. PubMed ID: 11555785
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    Scandinavian Breast Group Trial 9401Laboratory of Cancer Biology, Institute of Medical Technology, and Department of Oncology, Tampere University and Tampere University Hospital, Tampere, Finland., Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.
    J Clin Oncol; 2006 Jun 01; 24(16):2428-36. PubMed ID: 16682728
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C, von Struensee D, Bierer S, Bögemann M, Hertle L, Eltze E.
    Aktuelle Urol; 2005 Sep 01; 36(5):423-9. PubMed ID: 16163605
    [Abstract] [Full Text] [Related]

  • 39. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas.
    Ettl T, Schwarz S, Kleinsasser N, Hartmann A, Reichert TE, Driemel O.
    Histopathology; 2008 Nov 01; 53(5):567-77. PubMed ID: 18983466
    [Abstract] [Full Text] [Related]

  • 40. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome.
    Krüger S, Weitsch G, Büttner H, Matthiensen A, Böhmer T, Marquardt T, Sayk F, Feller AC, Böhle A.
    Int J Oncol; 2002 Nov 01; 21(5):981-7. PubMed ID: 12370744
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.